Sahiti Marella

Sahiti Marella

Auto-generated profile, based on publicly available information

Sahiti Marella

Department of Dermatology, University of Michigan, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
SMSahiti Marella
Sahiti Marella
MPMaksim V. Plikus
Maksim V. Plikus
JGJohann Gudjonsson
Johann Gudjonsson

15 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSahiti Marella
Sahiti Marella
RBRachael Bogle
Rachael Bogle
JFJennifer Fox
Jennifer Fox
LTLam Tsoi
Lam Tsoi
XXXianying Xing
Xianying Xing
JGJohann Gudjonsson
Johann Gudjonsson
Human skin is not a uniform organ but a mosaic of anatomically distinct niches, with each site finely tuned to unique environmental demands and immune pressures. Yet, the molecular determinants that define these regional identities and their relationship to site-specific vulnerability to inflammatory disease remain poorly understood. Here, we generate a high-resolution single-cell atlas of human skin, profiling 274,834 cells from 96 healthy samples across 7 anatomically distinct sites (acral, arm, axilla, back, face, leg and scalp). Our analysis reveals striking region-specific transcriptional and cellular networks, uncovering how local immune-stromal crosstalk governs tissue homeostasis and underpins anatomical susceptibility to distinct inflammatory diseases such as such as systemic lupus erythematosus (SLE), atopic dermatitis (AD), and psoriasis. These findings illuminate the tissue-intrinsic foundations of regional immune identity and provide a blueprint/resource for the development of precision therapies tailored to the distinct immunological microenvironments of specific anatomical skin sites.

20 July 2024 in Mucosal Immunology
Verified
Journal Article
Open access
GIGila Idelman
Gila Idelman
CRChristian F. Rizza
Christian F. Rizza
SMSahiti Marella
Sahiti Marella
ANKIT SHARMAANKIT SHARMA
ANKIT SHARMA
SCSomdutta Chakraborty
Somdutta Chakraborty
SHSimon P. Hogan
Simon P. Hogan
Mast cells (MCs) are derived from CD34+ hematopoietic progenitors, consist of different subtypes, and are involved in several inflammatory conditions. However, our understanding of human MC developmental trajectories and subtypes has been limited by a scarcity of suitable cellular model systems. Herein, we developed an in vitro model of human MC differentiation from induced pluripotent stem cells (iPSC) to study human MC differentiation trajectories. Flow cytometry characterization of hemopoietic cells derived from the myeloid cells-forming complex (MCFC) revealed an initial increase in Lin- CD34+ hematopoietic progenitors within Weeks 1-3, followed by an increase in CD34- CD45RA- SSClow and SSChigh hematopoietic cells. The Lin- CD34+ hematopoietic progenitors consisted of SSClow CD45RA- CD123± c-Kit+ FcεRI+ populations that were β7-integrinhigh CD203c+ and β7-integrinhigh CD203c- cells consistent with CMPFcεRI+ cells. Flow cytometry and cytologic analyses of the CD34- Lin- (SSClow) population revealed hypogranular cell populations, predominantly characterized by CD45RA- CD123± c-Kit+ FcεRI- β7-integrinlow and CD45RA- CD123± c-Kit- FcεRI+ β7-integrinMid cells. Analyses of hypergranular SSChigh cells identified Lin- CD34- CD45RA- c-Kit+ FcεRI- and Lin- CD34- CD45RA- c-Kit+ FcεRI+ cells. scRNA-seq analysis of the cells harvested at week 4 of the MCFC culture revealed the presence of monocyte and granulocyte progenitors (n = 547 cells, 26.7 %), Erythrocyte / unknown (n = 85, 4.1 %), neutrophils / myelocytes (n = 211 cells, 10.2 %), mast cell progenitor 1 (n = 599, 29.1 %), mast cell progenitor 2 (n = 152, 7.4 %), committed mast cell precursor (n = 113, 5.5 %), and MCs (n = 353, 17.1 %). In silico analyses of the MC precursor and mature MC populations revealed transcriptionally distinct MC precursor subtype and mature MC states (CMA1+ and CMA1- subtypes). Culturing MC precursor populations in MC maturation media (mast cell media II) led to homogenous mature MC populations as evidenced by high expression of high-affinity IgE receptor, metachromatic granules, presence of MC granule proteins (Tryptase and Chymase) and activation following substance P stimulation and FcεRI crosslinking. This human iPSC-based approach generates MC precursors and phenotypically mature and functional MC populations. This system will be a useful model to generate human MC populations and broaden our understanding of MC biology and transcriptional regulation of MC differentiation trajectories.

9 July 2026 in Journal of Experimental Medicine
Verified
Journal Article
Closed access
FAFlorence Assan
Florence Assan
MTMargot Tragin
Margot Tragin
SMSahiti Marella
Sahiti Marella
JLJoanna Lipecka
Joanna Lipecka
KRKevin Roger
Kevin Roger
HBHervé Bachelez
Hervé Bachelez
Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.

24 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSahiti Marella
Sahiti Marella
RBRachael Bogle
Rachael Bogle
HZHaihan Zhang
Haihan Zhang
JFJennifer Fox
Jennifer Fox
JKJoseph Kirma
Joseph Kirma
Eran Cohen-BarakEran Cohen-Barak
Eran Cohen-Barak
Targeted biologics have significantly advanced the treatment of inflammatory skin diseases such as psoriasis; however, some patients paradoxically develop eczematous skin reactions during or after anti-TNFα, IL-17, or IL-23 therapy. Although these paradoxical reactions resemble atopic dermatitis clinically and histologically, the molecular mechanisms that drive their development are not fully understood. Here, we generated high-resolution cellular and spatial maps of healthy skin, psoriasis, atopic dermatitis, and paradoxical reactions using single-cell RNA sequencing, spatial transcriptomics, immunohistochemistry, and in vitro assays. In paradoxical reactions, we identified a distinct transcriptional landscape characterized by myeloid and T-cell expansion and an altered keratinocyte phenotype shaped by TWEAK signaling. Mechanistically, we showed that TWEAK synergizes with IL-13 to drive the Th2/type I interferon-polarized epithelial program. Notably, anti-TNFα therapy induced TWEAK gene expression in myeloid cells, suggesting a compensatory inflammatory circuit. Together, these findings identify the TWEAK-IL-13 axis as a central driver of paradoxical skin reactions and provide a mechanistic framework for how cytokine blockade may rewire cutaneous immune responses. One Sentence Summary The TWEAK-IL-13 signaling axis is a key driver of immune reprogramming underlying paradoxical skin reactions.

4 November 2026 in Science Translational Medicine
Verified
Journal Article
Closed access
SMSahiti Marella
Sahiti Marella
RBRachael Bogle
Rachael Bogle
HZHaihan Zhang
Haihan Zhang
JFJennifer Fox
Jennifer Fox
JKJoseph Kirma
Joseph Kirma
Eran Cohen-BarakEran Cohen-Barak
Eran Cohen-Barak
Targeted biologics have transformed the treatment of inflammatory skin diseases such as plaque psoriasis. However, some patients with psoriasis paradoxically develop eczematous skin reactions after therapy targeting tumor necrosis factor (TNF), interleukin-17 (IL-17), or IL-23. Although paradoxical eczema (PE) resembles atopic dermatitis (AD) clinically and histologically, the molecular mechanisms that drive its development remain poorly understood. Here, we generated high-resolution cellular and spatial maps of human skin using single-cell RNA sequencing, spatial transcriptomics, immunohistochemistry, and in vitro assays, profiling lesional biopsies from patients with PE ( n = 8 donors), alongside healthy control, psoriasis, and AD skin ( n = 4 donors per group). In PE, we identified distinct transcriptional changes characterized by myeloid and T cell expansion and an altered keratinocyte phenotype shaped by TNF-like weak inducer of apoptosis (TWEAK; encoded by TNFSF12 ) signaling through its receptor TNFRSF12A , confirmed at the protein level by immunohistochemistry. To define the underlying mechanism, we stimulated immortalized (N-TERT) and primary human keratinocytes and found that TWEAK acted together with IL-13 to drive a T helper 2– and type I interferon–polarized epithelial program that partially recapitulated the keratinocyte signature of PE lesions. We validated key target genes by quantitative polymerase chain reaction in primary keratinocytes. In THP-1 cells and primary human CD14 + monocytes, anti-TNF treatment induced TWEAK expression, suggesting a compensatory inflammatory circuit. Together, these findings identify the TWEAK–IL-13 axis as a key driver of PE and suggest how cytokine blockade may reshape cutaneous immune responses.